(Q54374407)

English

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.

scientific article published on 27 February 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Toni K Choueiri

3

object named as

Toni K Choueiri

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

author name string

Jorge A Garcia

1

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Gary R Hudes

2

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Walter M Stadler

4

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Laura S Wood

5

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Jayne Gurtler

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Shailender Bhatia

7

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Adarsh Joshi

8

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Rebecca R Hozak

9

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Yihuan Xu

10

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Jonathan D Schwartz

11

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

John A Thompson

12

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

language of work or name

0 references

publication date

27 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

120

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

11

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

1647-1655

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28634

21 January 2018

Identifiers

10.1002/CNCR.28634

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24577874

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54374407&oldid=1531323609"